Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira-Enabled Non-RNAi Drugs Acquired by Spectrum Pharmaceuticals


Tekmira Pharmaceuticals this week announced that Talon Therapeutics, which licensed certain of the company’s legacy, non-RNAi drug candidates, will be acquired by Spectrum Pharmaceuticals.

According to Tekmira, Spectrum has stated that it intends to launch one of those drugs, the liposome-formulated chemotherapeutic Marqibo, later this year through its own sales force. Tekmira received a $1 million milestone payment last year from Talon related to the US Food and Drug Administration approval of Marqibo, and stands to receive royalties from Spectrum on the product’s sales.

"The future sales of Marqibo represent a recurring revenue stream for Tekmira,” Tekmira President and CEO Mark Murray said in a statement.

Through its acquisition of Talon, Spectrum has also picked up two other drug candidates, one in phase I testing and one still preclinical, for which Tekmira is eligible for milestones and royalties.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.